SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) Financing Receivable, Collectively Evaluated for Impairment

Prices Financial Statements ›Discontinued ›News Ratios Analyst Ratings Insider Transactions SEC Filings Roast Me Breakdown

Balance Sheet ›Income Statement ›Expense Statement ›Shareholders' Equity ›Cash Flow ›Notes ›

US Government Agencies Securities, at Carrying Value Receivables ›Payables and Accruals ›Revenue Recognition, Sales Returns, Reserve for Sales Returns Other Commitment Debt ›Other Liabilities ›Equity ›Compensation Related Costs ›Components of Deferred Tax Assets and Liabilities ›Fair Value Disclosures ›Transfers and Servicing of Financial Assets ›Financial Services ›Accruals Adjustments For Increase Decrease In Employee Benefit Liabilities Adjustments For Increase Decrease In Other Operating Payables Advances Amounts Payable Related Party Transactions Assets Auditors Remuneration Capital Commitments Capital Redemption Reserve Cash Cash Flows From Used In Decrease Increase In Shortterm Deposits And Investments Cash Flows From Used In Operations Leases ›Contributions To Plan Net Defined Benefit Liability Asset Current Assets Current Financial Liabilities Current Liabilities Current Prepaid Expenses Current Prepayments And Other Current Assets Current Restricted Cash And Cash Equivalents Description Of Expected Volatility Share Options Granted Description Of Risk Free Interest Rate Share Options Granted Entity Public Float Equity Equity And Liabilities Equity Attributable To Owners Of Parent Financial Assets Financial Assets At Fair Value Through Profit Or Loss Financial Liabilities Financial Liabilities At Amortised Cost General Fair Value Hedge Information, Minimum R Square, Percentage Government Grants Increase Decrease Through Exercise Of Options Increase Decrease Through Exercise Of Warrants Equity Investment Funds Amount Contributed To Fair Value Of Plan Assets Issue Of Convertible Instruments Issue Of Equity Liabilities Arising From Financing Activities Noncurrent Assets Noncurrent Financial Liabilities Noncurrent Government Grants Noncurrent Liabilities Noncurrent Provisions For Employee Benefits Number Of Employees Number Of Outstanding Share Options Number Of Shares Issued Other Cash And Cash Equivalents Other Cash Payments From Operating Activities Other Longterm Benefits Other Noncurrent Assets Other Noncurrent Financial Assets Other Payables Other Reserves Par Value Per Share Profit Loss From Continuing Operations Raw Materials And Consumables Used Reclassification Adjustments On Availableforsale Financial Assets Net Of Tax Restricted Cash And Cash Equivalents Retained Earnings Rightofuse Assets Rightofuse Assets Increase Decrease In Revaluation Surplus Secured Bank Loans Received Share Premium Tax Rate Effect From Change In Tax Rate Tax Rate Effect Of Tax Losses Trade And Other Current Payables Trade And Other Payables Wages And Salaries

and Others ›Adjustments For Decrease Increase In Trade And Other Receivables Loans And Receivables Trade And Other Current Receivables

Financing Receivable, Collectively Evaluated for Impairment Loans Receivable with Variable Rates of Interest Other Receivables, Net, Current

SCINAI IMMUNOTHERAPEUTICS LTD. Financing Receivable, Collectively Evaluated for Impairment

SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) had Financing Receivable, Collectively Evaluated for Impairment of $29.44 million as of 2020-12-31, per its 10-Q filed 2023-05-15.

Discontinued › Notes › Receivables › and Others

us-gaap:FinancingReceivableCollectivelyEvaluatedForImpairment · last filed 2023-05-15

2020-12-31: Financing Receivable, Collectively Evaluated for Impairment $29.44M.

Period end	Financing Receivable, Collectively Evaluated for Impairment
2020-12-31	$29.44M 10-Q · filed 2023-05-15